TBA Law Blog


Posted by: Brittany Sims on Aug 1, 2013

Tennessee will receive $768,890 as its share of a $409.9 million False Claims Act settlement reached between the federal government and Wyeth Pharmaceuticals Inc., the Nashville Business Journal reports. The settlement resolves allegations of off-label marketing of Rapamune, an “immunosuppressive” drug that prevents the body’s immune system from rejecting a transplanted organ. According to the state Attorney General's office, Rapamune is FDA-approved for kidney transplants. Wyeth was named in civil and criminal proceedings for allegedly illegally promoting the sale and use of Rapamune for use in other organ transplant cases besides kidneys.